GLP-1 Agonist Therapy Center

Could GLP-1 inhibitors be a useful adjunct therapy in type I diabetes?

A phase 2 randomized controlled trial demonstrated clinically significant changes in glycemic control.

Female 43 years of age. Type 1 diabetes/insulin resistant, hyperglycemia, increasing insulin to manage glucose, but not covering well. Increasing appetite and gaining weight. GLP-1 (Victoza) added at 1/2 recommended start dose for people who have type 2 diabetes, which is 0.6mg, so patient started at 0.3mg daily. Patient started having hypoglycemic reactions, most often postprandially and nocturnally.

Cardioprotective effects of the drug are focus of research.

Does insulin cause more deaths and cardiovascular outcomes than GLP-1 agonist receptors?

LEADER showed liraglutide reduces risk of cardiovascular death, but latest study shows no benefit to high-risk patients.

63-year-old male, moderate cognitive impairment and lives alone. Patient lost a significant amount of weight, frequent symptomatic hypoglycemia, including light-headedness and dizziness, requiring lowering and stopping some of his glucose lowering medications. GLP-1 was stopped and his glucose levels were in normal range. We were very clear that he should not resume his GLP-1 until we saw him again.

With Sanofi's LixiLan® filed for FDA approval, GLP-1 agonist/basal insulin combinations may be potential game changers.

Novo Nordisk announced positive results on its pipeline GLP-1 candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4 and 5.

First a little explanation about the new unique product with its own delivery system. This is not only a medication but also a matchstick-sized osmotic mini pump that is the size of a match and is placed just beneath the skin to deliver a continuous and consistent flow of medication for a year.